Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol Ther. 2012 Feb; 20(2):347-55.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.